INITIAL RESULTS FROM A PHASE 2 STUDY OF CARFILZOMIB, LENALIDOMIDE, AND LOW-DOSE DEXAMETHASONE (KRD) PLUS AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM)

被引：0

作者：

Zimmerman, T. M. ^{[1
]}

Griffith, K. ^{[2
]}

Jasielec, J. K. ^{[1
]}

Rosenbaum, C. A. ^{[1
]}

McDonnell, K. ^{[1
]}

Marin, J. ^{[1
]}

Bakker, J. ^{[1
]}

Berdeja, J. G. ^{[3
]}

Vij, R. ^{[4
]}

Jakubowiak, A. J. ^{[1
]}

机构：

[1] Univ Chicago, Chicago, IL 60637 USA

[2] Univ Michigan, Ann Arbor, MI 48109 USA

[3] Sarah Cannon Canc Ctr, Nashville, TN USA

[4] Washington Univ, St Louis, MO USA

来源：

HAEMATOLOGICA | 2014年 / 99卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

P347

引用

页码：103 / 103

页数：1

共 50 条

[1] Final Results of a Phase 2 Trial of Extended Treatment (tx) with Carfilzomib (CFZ), Lenalidomide (LEN), and Dexamethasone (KRd) Plus Autologous Stem Cell Transplantation (ASCT) in Newly Diagnosed Multiple Myeloma (NDMM)
Zimmerman, Todd
Raje, Noopur S.
Vij, Ravi
Reece, Donna
Berdeja, Jesus G.
Stephens, Leonor A.
McDonnell, Kathryn
Rosenbaum, Cara A.
Jasielec, Jagoda
Richardson, Paul G.
Gurbuxani, Sandeep
Nam, Jennifer
Severson, Erica
Wolfe, Brittany D.
Rosebeck, Shaun
Stefka, Andrew
Dytfeld, Dominik
Griffith, Kent
Jakubowiak, Andrzej
[J]. BLOOD, 2016, 128 (22)
[2] Final Analysis of a Phase 2 Trial of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma (NDMM) without Autologous Stem Cell Transplantation (ASCT)
Derman, Benjamin A.
Cooperrider, Jennifer H.
Rosenblatt, Jacalyn
Avigan, David
Rampurwala, Murtuza M.
Major, Ajay
Karrison, Theodore
Jiang, Ken
Kubicki, Tadeusz
Jakubowiak, Andrzej J.
[J]. BLOOD, 2023, 142
[3] Lenalidomide and low-dose dexamethasone (Ld) is equivalent to Ld plus autologous stem cell transplant (ASCT) in newly diagnosed multiple myeloma (NDMM): Results of a randomized, phase III trial
Lentzsch, Suzanne
Miao, Susanna
Schecter, Jordan Mark
Griffith, Kent A.
Normolle, Daniel Paul
Mapara, Markus Y.
Redner, Robert L.
Villanueva, Nicolas
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[4] Phase II MMRC trial of extended treatment with carfilzomib (CFZ), lenalidomide (LEN), and dexamethasone (DEX) plus autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma (NDMM).
Zimmerman, Todd M.
Griffith, Kent A.
Jasielec, Jagoda
Rosenbaum, Cara Ann
McDonnell, Kathryn
Waite-Marin, Jessica
Berdeja, Jesus G.
Raje, Noopur S.
Reece, Donna Ellen
Vij, Ravi
Alonge, Mattina
Rosebeck, Shaun
Gurbuxani, Sandeep
Faham, Malek
Kong, Katherine A.
Levy, Joan
Jakubowiak, Andrzej J.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[5] Carfilzomib (CFZ, Kyprolis®), Lenalidomide (LEN, Revlimide®), and Dexamethasone (DEX) (KRd) Combined with Autologous Stem Cell Transplant (ASCT) Shows Improved Efficacy Compared with Krd without ASCT in Newly Diagnosed Multiple Myeloma (NDMM)
Zimmerman, Todd M.
Griffith, Kent
Jasielec, Jagoda K.
Rosenbaum, Cara A.
Berdeja, Jesus G.
Vij, Ravi
Raje, Noopur
Reece, Donna E.
Vesole, David H.
Jagannath, Sundar
Kaminski, Mark
Cole, Craig
Nam, Jennifer
Stephens, Leonor A.
Rosebeck, Shaun
Gurbuxani, Sandeep
Dytfeld, Dominik
Jakubowiak, Andrzej J.
[J]. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2016, 22 (03) : S40 - S40
[6] Frontline Therapy with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Induction Followed By Autologous Stem Cell Transplantation, Krd Consolidation and Lenalidomide Maintenance in Newly Diagnosed Multiple Myeloma (NDMM) Patients: Primary Results of the Intergroupe Francophone Du MyeLome (IFM) Krd Phase II Study
Roussel, Murielle
Lauwers-Cances, Valerie
Robillard, Nelly
Belhadj, Karim
Facon, Thierry
Garderet, Laurent
Escoffre, Martine
Pegourie, Brigitte
Benboubker, Lotfi
Caillot, Denis
Fohrer, Cecile
Moreau, Philippe
Leleu, Xavier
Avet-Loiseau, Herve
Attal, Michel
[J]. BLOOD, 2016, 128 (22)
[7] Carfilzomib, lenalidomide, and low-dose dexamethasone in elderly patients with newly diagnosed multiple myeloma
Dytfeld, Dominik
Jasielec, Jagoda
Griffith, Kent A.
Lebovic, Daniel
Vesole, David H.
Jagannath, Sundar
Al-Zoubi, Ammar
Anderson, Tara
Detweiler-Short, Kristen
Stockerl-Goldstein, Keith
Ahmed, Asra
Jobkar, Terri
Durecki, Diane E.
McDonnell, Kathryn
Mietzel, Melissa
Couriel, Daniel
Kaminski, Mark
Vij, Ravi
Jakubowiak, Andrzej J.
[J]. HAEMATOLOGICA, 2014, 99 (09) : E162 - E164
[8] IMPROVED EFFICACY AFTER INCORPORATING AUTOLOGOUS STEM CELL TRANSPLANT (ASCT) INTO KRD TREATMENT WITH CARFILZOMIB (CFZ), LENALIDOMIDE (LEN), AND DEXAMETHASONE (DEX) IN NEWLY DIAGNOSED MULTIPLE MYELOMA
Jakubowiak, A.
Raje, N.
Vij, R.
Reece, D.
Berdeja, J.
Vesole, D.
Jagannath, S.
Cole, C.
Faham, M.
Nam, J.
Stephens, L.
Severson, E.
Revethis, A.
Wolfe, B.
Rosebeck, S.
Gurbuxani, S.
Rosenbaum, C.
Jasielec, J.
Dytfeld, D.
Griffith, K.
Zimmerman, T.
[J]. HAEMATOLOGICA, 2016, 101 : 1 - 2
[9] Carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) for initial therapy of newly diagnosed multiple myeloma (NDMM): Results of ENDURANCE (E1A11) phase III trial
Jacobus, Susanna J.
Cohen, Adam D.
Weiss, Matthias
Callander, Natalie Scott
Singh, Avina A.
Parker, Terri L.
Menter, Alex R.
Yang, Xuezhong
Parsons, Benjamin Marshall
Kumar, Pankaj
Kapoor, Prashant
Rosenberg, Aaron Seth
Zonder, Jeffrey A.
Faber, Edward Anthony
Lonial, Sagar
Richardson, Paul G.
Orlowski, Robert Z.
Wagner, Lynne I.
Rajkumar, S. Vincent
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (18)
[10] Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd), autologous transplantation and MRD response-adapted treatment duration and cessation in newly diagnosed Multiple Myeloma (NDMM)
Costa, Luciano
Chhabra, Saurabh
Medvedova, Eva
Dholaria, Bhagirathbhai
Schmidt, Timothy
Silbermann, Rebecca
Godby, Kelly
Dhakal, Binod
Bal, Susan
Giri, Smith
D'Souza, Anita
Cornell, Robert
Hardwick, Pamela
Omel, James
Hari, Parameswaran
Callander, Natalie S.
[J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S33 - S33

← 1 2 3 4 5 →